Triple DMARD Therapy for Rheumatoid Arthritis

Introduction to Triple DMARD Therapy

The American College of Rheumatology recommends triple DMARD therapy, consisting of methotrexate, sulfasalazine, and hydroxychloroquine, for patients with rheumatoid arthritis who have an inadequate response to methotrexate monotherapy, with a dosing regimen of methotrexate 15-25 mg weekly, sulfasalazine 2 g daily, and hydroxychloroquine 200 mg daily 1, 2

The initial dose of methotrexate should be 15 mg weekly, with titration to at least 15 mg within 4-6 weeks, and further escalation to 20-25 mg weekly as tolerated to optimize efficacy, according to the American College of Rheumatology 1, 2, 3
Oral administration is preferred initially, but switch to subcutaneous route if inadequate response at maximum tolerated oral dose or if gastrointestinal intolerance occurs, as recommended by the American College of Rheumatology 1, 2, 3
At least 5 mg folic acid weekly should be prescribed to reduce gastrointestinal and hepatic toxicity without compromising efficacy, as suggested by the European League Against Rheumatism 4

Triple DMARD therapy should be initiated when patients have inadequate response to methotrexate monotherapy at optimized doses, particularly in those with moderate disease activity, according to the American College of Rheumatology 1, 2

Allow 3-6 months to fully assess efficacy of triple therapy before considering it a failure, as recommended by the American College of Rheumatology 1, 2
Monitor liver enzymes, creatinine, and complete blood count every 1-1.5 months during dose escalation, then every 1-3 months once stable, according to the European League Against Rheumatism 4
If sulfasalazine needs to be discontinued from triple therapy, it should be the first drug removed rather than hydroxychloroquine, as sulfasalazine has poorer treatment persistence, as suggested by the American College of Rheumatology 6, 7, 8
Triple therapy can be safely continued long-term in patients who achieve and maintain disease control, according to the European League Against Rheumatism 4

The 2021 ACR guidelines conditionally recommend adding biologics or targeted synthetics over triple therapy, but triple therapy remains a highly effective and cost-efficient option, particularly for patients with moderate disease activity, as stated by the American College of Rheumatology 5, 3